Valsartan is a widely used, efficacious and very well-tolerated antihypertensive agent. By
specifically blocking the action of angiotensin II on the angiotensin Type 1 receptor …

A total of 501 elderly patients with essential hypertension were randomized to receive
valsartan or lisinopril in this one year multi-center, double-blind, parallel group trial. Patients …

Valsartan is a specific angiotensin II receptor antagonist with high selectivity for the AT 1
receptor subtype. After oral administration of single or repeated once-daily doses, valsartan …

Synopsis Valsartan competitively and selectively inhibits the actions of angiotensin II at the
AT 1 receptor subtype which is responsible for most of the known effects of angiotensin II. In …

Valsartan is a highly selective, orally available antagonist of the angiotensin Type 1 (AT1)
receptor. It is indicated for treatment of mild to moderate essential hypertension …

Valsartan is an angiotensin receptor antagonist that specifically blocks the angiotensin II
type 1 receptors. It is an effective and well-tolerated once-daily antihypertensive agent, with …

Valsartan is the second orally-active, non-peptide angiotensin II receptor blocker to reach
the market in Europe and the USA for the treatment of hypertension. Preclinical studies have …

Valsartan is a nonpeptide angiotensin receptor antagonist that selectively blocks the binding
of angiotensin II to the angiotensin II type 1 receptor. The efficacy, tolerability and safety of …

In the main Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) report, we
investigated outcomes in 15 245 high-risk hypertensive subjects treated with valsartan-or …

Background: Recent data suggest that use of relatively high doses of angiotensin II-receptor
blockers (ARBs) in hypertensive patients at high cardiovascular risk may reduce the …